Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Board Changes

1 Jul 2020 07:00

RNS Number : 6223R
Ideagen PLC
01 July 2020
 

July 1st 2020

 

 

Ideagen PLC

("Ideagen" "the Company" or "the Group")

 

Board Change

 

Ideagen PLC (AIM: IDEA), a leading supplier of integrated risk management software to highly regulated industries, is pleased to confirm that Emma Hayes has today joined the Group as Chief Financial Officer, succeeding Graeme Spenceley, as announced on 7th January 2020.

 

Graeme has retired as a Director but will remain with the Group as Company Secretary and financial advisor to the Board. This role will be on a full-time basis until 31 October 2020 which will provide for a full and effective handover to Emma, and thereafter he will continue in that capacity on a part-time basis.

 

Emma was previously Group Finance Director, Capital Delivery and Commercial, at Severn Trent PLC having held the position since 2017. In this role she controlled a P&L and Balance Sheet of approximately £600m and was responsible for driving operational efficiencies through her 100-strong team. Before that Emma spent 10 years with Deloitte LLP as a Corporate Finance Director where she led origination and execution of a wide range of M&A transactions. Emma qualified as a Chartered Accountant (ACA) with BDO.

Graeme Spenceley was previously awarded 750,000 share options under the Company's 2018 LTIP scheme (as announced on 29 March 2019 with details of the relevant scheme announced on 23 October 2018). The Board and Graeme have agreed that this award will be reduced to 187,500 options and that these will vest in full on the achievement of the first performance criteria (being the Company's share price reaching 196 pence over 30 consecutive business days).

Emma has in turn been awarded 562,500 share options under the 2018 LTIP with the same vesting conditions such that 187,500 of these options becoming eligible to vest on the first performance criterion described above being met, with the remainder becoming eligible to vest on the Company's share price reaching 259 pence over 30 consecutive business days. All other terms and conditions relating to the 2018 LTIP as previously described apply equally.

 

Ben Dorks, Chief Executive of Ideagen, commented; "Firstly, the Board would like thank Graeme for his outstanding commitment to Ideagen. His insight, acumen and support over the past 10 years has been invaluable and it has been a great pleasure to work alongside him. We are pleased that Graeme will remain with the business as Company Secretary which will provide for a robust transition.

 

The Board is delighted to welcome Emma to the Group who brings with her a deep understanding of both financial structures and processes and M&A. We will benefit hugely from Emma's experience and ability as Ideagen continues to execute its global growth strategy.''

 

There are no further disclosures to be made in relation to Emma Jane Hayes, aged 39, pursuant to Schedule 2(g) of the AIM Rules for Companies. .

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

 

Ben Dorks, Chief Executive Officer

 

Graeme Spenceley, Chief Financial Officer

 

 

 

 finnCap Limited

020 7220 0500

Henrik Persson/James Thompson/ Hannah Boros (Nomad)

 

Alice Lane (ECM)

 

 

Canaccord Genuity Limited

 020 7523 8000

Simon Bridges

 

Richard Andrews

 

 

 

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides IRM software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 4,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Emma Hayes

2.

Reason for the notification

a)

Position/status:

Chief Financial Officer

b)

Initial notification/Amendment:

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Ideagen plc

 

b)

LEI:

213800KS1MLITOVNYC85

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 0.1p

 

GB00B0CM0C50

b)

Nature of the transaction:

Grant of LTIPs over Ordinary Shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

n/a

562,500

 

d)

Aggregated information:

· Aggregated volume:

· Price:

See 4 (c) above

e)

Date of the transaction:

1 July 2020

 

f)

Place of the transaction:

Off market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFFFEIRLIIVII
Date   Source Headline
22nd Oct 201911:26 amRNSHolding(s) in Company
17th Oct 20193:32 pmRNSDirector/PDMR Shareholding
11th Oct 20197:00 amRNSAcquisition of Optima Diagnostics Limited
7th Oct 20193:29 pmRNSNotice of AGM
4th Oct 201910:45 amRNSExercise of Options, Issue of Shares and TVR
1st Oct 20197:00 amRNSExercise of Options, Issue of Shares and TVR
25th Sep 20197:00 amRNSRedland Acquisition Update - New Contract Wins
17th Sep 20197:00 amRNSDirector Dealing and Total Voting Rights
13th Sep 201912:08 pmRNSIssue of shares under the Share Incentive Plan
3rd Sep 20198:48 amRNSHolding(s) in Company
27th Aug 20192:21 pmRNSExercise of Options and Issue of Shares
14th Aug 20194:04 pmRNSIssue of New Shares under the Share Incentive Plan
30th Jul 201912:26 pmRNSHolding(s) in Company
22nd Jul 20194:20 pmRNSIssue of New Shares under the Share Incentive Plan
17th Jul 20197:00 amRNSPreliminary Results
19th Jun 201910:24 amRNSHolding(s) in Company
10th Jun 20197:00 amRNSAcquisition of Redland Solutions Ltd
30th May 20197:00 amRNSContract Award with New Tier 1 Airline Customer
15th May 20197:00 amRNSCapital Markets Day
14th May 20197:00 amRNSTrading Statement
12th Apr 20192:43 pmRNSDirector Dealings
11th Apr 20195:06 pmRNSIssue of Shares, Director Dealings and TVR
29th Mar 20197:00 amRNSExtension to 2018 Long Term Incentive Plan awards
25th Feb 20198:00 amRNSExercise of Options and Issue of Shares
30th Jan 201910:03 amRNSExercise of Options and issue of shares
28th Jan 20194:33 pmRNSIssue of new shares under the Share Incentive Plan
22nd Jan 20197:00 amRNSUnaudited Interim Results
21st Jan 20198:46 amRNSHolding(s) in Company
15th Jan 20197:00 amRNSAppointment of Joint Broker
14th Jan 20197:00 amRNSAcquisition of Scannell Solutions Ltd
11th Dec 20183:37 pmRNSIssue of Shares, Director Dealings and TVR
5th Dec 20182:54 pmRNSHolding(s) in Company
22nd Nov 201812:12 pmRNSHolding(s) in Company
21st Nov 20187:57 amRNSHolding(s) in Company
20th Nov 201812:04 pmRNSHolding(s) in Company
19th Nov 20185:56 pmRNSHolding(s) in Company
13th Nov 20187:00 amRNSTrading Update
30th Oct 20182:28 pmRNSResult of AGM
24th Oct 20182:35 pmRNSExercise of Options and Total Voting Rights
23rd Oct 201811:19 amRNSHolding(s) in Company
23rd Oct 20187:00 amRNS2018 Long Term Incentive Plan awards
12th Oct 20183:26 pmRNSHolding(s) in Company
10th Oct 20184:18 pmRNSHolding(s) in Company
8th Oct 201812:46 pmRNSIssue of Shares and Total Voting Rights
8th Oct 20187:00 amRNSPosting of Annual Report and Notice of AGM
5th Oct 20187:00 amRNSDirectors' Dealings
3rd Oct 20184:36 pmRNSExercise of Options & Total Voting Rights
2nd Oct 20184:38 pmRNSHolding(s) in Company
2nd Oct 20184:37 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSAcquisition of Morgan Kai Group Ltd

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.